Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - A prospective cohort study

BMC Public Health

Volumn 11, Issue , 2011, Pages

  El Khatib, Ziad ^a,b   Ekstrom, Anna Mia ^a   Coovadia, Ashraf ^c   Abrams, Elaine J ^d   Petzold, Max ^e   Katzenstein, David ^f   Morris, Lynn ^b   Kuhn, Louise ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Columbia University ^*  (United States)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; VIRAL LOAD;

EID: 79551681069     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-88     Document Type: Article

References (54)

1. Towards universal access - Scaling up priority HIV/AIDS interventions in the health sector (progress report 2009). Geneve. World Health Organization (WHO), UNAIDS, UNICEF, 2009
2. AIDS epidemic update. Geneve. World Health Organization (WHO), 2009
3. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. M Dembele N Saleri AC Carvalho T Saouadogo AD Hien I Zabsonre ST Koala J Simpore A Matteelli, Int J Tuberc Lung Dis 2010 14 318 323 20132623
4. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. AS Muula TJ Ngulube S Siziya CM Makupe E Umar HW Prozesky CS Wiysonge RH Mataya, BMC Public Health 2007 7 63 10.1186/1471-2458-7-63 17459154
5. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. M Cornell L Myer R Kaplan L Bekker R Wood, Trop Med Int Health 2009 14 722 731 10.1111/j.1365-3156.2009.02290.x 19413745
6. Gender differences in discontinuation of antiretroviral treatment regimens. MC Kempf M Pisu A Dumcheva AO Westfall JM Md MS Saag, J Acquir Immune Defic Syndr 2009 52 336 341 10.1097/QAI.0b013e3181b628be 19654551
7. Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the women's interagency HIV study. D Merenstein M Schneider C Cox R Schwartz K Weber E Robison M Gandhi J Richardson P MW, AIDS Patient Care and STDs 2009 23 289 296 10.1089/apc.2008.0161 19243274
8. Social support, coping, and medication adherence among HIV-positive women with depression living in rural areas of the southeastern United States. M Vyavaharkar L Mone (Pubitemid 47525390)
9. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. LK Murray K Semrau E McCurley DM Thea N Scott M Mwiya C Kankasa J Bass P Bolton, AIDS Care 2009 21 78 86 10.1080/09540120802032643 19085223
10. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Shuter, Journal of Antimicrobial Chemotherapy 2008 61 4 769 73 10.1093/jac/dkn020 18256112 (Pubitemid 351426058)
11. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. DL Paterson S Swindells J Mohr M Brester EN Vergis C Squier MM Wagener N Singh, Ann Intern Med 2000 136 21 30 (Pubitemid 30432540)
12. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. JB Nachega M Hislop DW Dowdy RE Chaisson L Regensberg G Maartens, Ann Intern Med 2007 146 564 574 17438315
13. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Shuter J Sarlo T Kanmaz R Rode B Zingman, J Acquir Immune Defic Syndr 2007 45 4 8 10.1097/QAI.0b013e318050d8c2 17460469 (Pubitemid 46684437)
14. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: A prospective cohort study. M Martin E Del Cacho C Codina M Tuset E De Lazzari J Mallolas JM Miro JM Gatell J Ribas, AIDS Res Hum Retrovirus 2008 24 1263 1268 10.1089/aid.2008.0141
15. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. DR Bangsberg, Clin Infect Dis 2006 43 939 941 10.1086/507526 16941380 (Pubitemid 44435526)
16. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. VD Lima R Harrigan M Murray DM Moore E Wood RS Hogg JS Montaner, AIDS 2008 22 2371 2380 10.1097/QAD.0b013e328315cdd3 18981777
17. Adherence to triple therapy and viral load response. S Low-Beer B Yip M O'Shaughnessy R Hogg J Montaner, J Acquir Immune Defic Syndr 2000 23 360 361 10836763 (Pubitemid 30327043)
18. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. DR Bangsberg AR Moss SG Deeks, J Antimicrob Chemother 2004 53 696 699 10.1093/jac/dkh162 15044425 (Pubitemid 38660267)
19. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. N Ford M Darder T Spelman E Maclean E Mills A Boulle, PLoS One 2010 5 10460 10.1371/journal.pone.0010460 20485480
20. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. S Lockman RL Shapiro LM Smeaton C Wester I Thior L Stevens F Chand J Makhema C Moffat A Asmelash, et al. N Engl J Med 2007 356 135 147 10.1056/NEJMoa062876 17215531 (Pubitemid 46089674)
21. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. M Lallemant G Jourdain S Le Coeur JY Mary N Ngo-Giang-Huong S Koetsawang S Kanshana K McIntosh V Thaineua, N Engl J Med 2004 351 217 228 10.1056/NEJMoa033500 15247338
22. Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months. N Chintu MJ Giganti NB Putta M Sinkala E Sadoki EM Stringer JS Stringer BH Chi, Trop Med Int Health 2010 15 842 847 10.1111/j.1365-3156.2010.02540.x 20487418
23. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to Nonnucleoside Reverse-Transcriptase Inhibitor-based therapy. A Coovadia G Hunt EJ Abrams G Sherman T Meyers G Barry E Malan B Marais R Stehlau J Ledwaba, et al. Clin Infect Dis 2009 48 462 472 10.1086/596486 19133804
24. Health-related quality of life among people with HIV disease: results from the multicenter AIDS cohort study. E Bing R Hays L Jacobson B Chen S Gange N Kass J Chmiel S Zucconi, Qual Life Res 2000 9 55 63 10.1023/A:1008919227665 10981206 (Pubitemid 30670649)
25. SF-36 health survey manual and interpretation guide. J Ware K Snow M Kosisnki B Gandek, Boston: The Health Institute 1993
26. ACTG QOL 601-602 (QOL 601-2) Health Survey Manual. ACTG Outcomes Committee, 1999
27. Use of pharmacy refill data as a measure of antiretroviral adherence. R Grossberg R Gross, Current HIV/AIDS Reports 2007 4 187 191 10.1007/s11904-007- 0027-4 18366950
28. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. JB Nachega DM Stein DA Lehman D Hlatshwayo R Mothopeng RE Chaisson AS Karstaedt, AIDS Res Hum Retrovirus 2004 20 1053 1056 10.1089/aid.2004.20. 1053 (Pubitemid 39392009)
29. Antiretroviral failure despite high levels of adherence: Discordant adherence-response relationship in Botswana. GP Bisson A Rowh R Weinstein T Gaolathe I Frank R Gross, J Acquir Immune Defic Syndr 2008 49 107 110 10.1097/QAI.0b013e3181820141 18667926
30. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America. EJ Mills JB Nachega I Buchan J Orbinski A Attaran S Singh B Rachlis P Wu C Cooper L Thanane, et al. JAMA 2006 296 679 690 10.1001/jama.296.6.679 16896111 (Pubitemid 44200639)
31. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. Z El-Khatib AM Ekstrom J Ledwaba L Mohapi F Laher A Karstaedt S Charalambous M Petzold D Katzenstein L Morris, AIDS 2010 24 1679 1687 10.1097/QAD.0b013e32833a097b 20453629
32. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. DR Bangsberg EP Acosta R Gupta D Guzman ED Riley PR Harrigan N Parkin SG Deeks, AIDS 2006 20 223 231 10.1097/01.aids.0000199825.34241.49 16511415
33. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. JB Nachega M Hislop H Nguyen DW Dowdy RE Chaisson L Regensberg M Cotton G Maartens, J Acquir Immune Defic Syndr 2009 51 65 71 10.1097/QAI.0b013e318199072e 19282780
34. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. EM Gardner WJ Burmana JF Steiner PL Andersond DR Bangsberg, AIDS 2009 23
35. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. G Jourdain N Ngo-Giang-Huong S Le Coeur C Bowonwatanuwong P Kantipong P Leechanachai S Ariyadej P Leenasirimakul S Hammer M Lallemant Perinatal HIV Prevention Trial Group, N Engl J Med 2007 356 135 147 10.1056/NEJMoa062876 17215531
36. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. PA Coffie B Tonwe-Gold AK Tanon C Amani-Bosse G Bedikou EJ Abrams F Dabis DK Ekouevi, BMC Infect Dis 2010 10 188 20576111
37. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. MI Datay A Boulle D Mant P Yudkin, J Acquir Immune Defic Syndr 2010 54 489 495 10.1097/QAI.0b013e3181d91788 20395870
38. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva. World Health Organization (WHO), 2010
39. Antiretroviral therapies in women after single-dose nevirapine exposure. S Lockman MD Hughes J McIntyre Y Zheng T Chipato F Conradie F Sawe A Asmelash MC Hosseinipour L Mohapi, et al. N Engl J Med 2010 363 1499 1509 10.1056/NEJMoa0906626 20942666
40. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. M Vaz S Barros R Palacios J Senise L Lunardi A Amed A Castelo, Int J STD AIDS 2007 18 28 32 10.1258/095646207779949808 17326859
41. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV. C Zorrilla L Santiago D Knubson K Liberatore G Estronza O Colán M Acevedo, Cell Mol Biol (Noisy-le-grand) 2003 49 1187 1192 14983985
42. Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program. M Nassali D Nakanjako D Kyabayinze J Beyeza A Okoth T Mutyaba, AIDS Care 2009 21 1124 1131 10.1080/09540120802707467 20024771
43. Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa. K Peltzer M Mlambo N Phaswana-Mafuya R Ladzani, Acta Paediatr 2010 99 699 704 20146724
44. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. SC Kalichman B Ramachandran S Catz, J Gen Intern Med 1999 14 267 273 10.1046/j.1525-1497.1999.00334.x 10337035 (Pubitemid 29226671)
45. A prospective study of predictors of adherence to combination antiretroviral medication. CE Golin H Liu RD Hays LG Miller CK Beck J Ickovics AH Kaplan NS Wenger, J Gen Intern Med 2002 17 756 765 10.1046/j.1525-1497.2002. 11214.x 12390551 (Pubitemid 35286241)
46. Factors influencing adherence to anti-retroviral treatment in children with human immunodeficiency virus in South India - a qualitative study. K Paranthaman N Kumarasamy D Bella P Webster, AIDS Care 2009 21 1025 1031 10.1080/09540120802612857 20024759
47. The social grants and black women in South Africa: a case study of Bophelong township in Gauteng (PhD thesis). M van Driel, The University of Witwatersrand, Social sciences 2009
48. Explaining adherence success in sub-Saharan Africa: An ethnographic study. NC Ware J Idoko S Kaaya IA Biraro MA Wyatt O Agbaji G Chalamilla DR Bangsberg, PLoS Med 2009 6 11 10.1371/journal.pmed.1000011 19175285
49. The STARK study: a cross-sectional study of adherence to short-term drug regiments in urban Kenya. AE Ellis RP Gogel BR Roman JB Watson D Indyk G Rosenberg, Soc Work Health Care 2006 42 237 250 10.1300/J010v42n03-15 16687385 (Pubitemid 44161883)
50. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. EJ Mills JB Nachega DR Bangsberg S Singh B Rachlis P Wu K Wilson L Buchan CJ Gill C Cooper, PLoS Med 2006 3 1 26 10.1371/journal.pmed.0030001 (Pubitemid 43200628)
51. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. S Rosen M Ketlhapile I Sanne MB Desilva, J Int Assoc Physicians AIDS Care (Chic Ill) 2008 7 200 207 10.1177/1545109708320684
52. P4P4P: An agenda for research on pay-for-performance for patients. K Volpp M Pauly G Loewenstein DR Bangsberg, Health Affair 2009 28 206 214 10.1377/hlthaff.28.1.206
53. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Rosen M Ketlhapile I Sanne MB DeSilva, S Afr Med J 2007 97 524 529 17805455 (Pubitemid 47091191)
54. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. A Amberbir K Woldemichael S Getachew B Girma K Deribe, BMC Health Serv Res 2008 8 265 19094244